- Home
- BZFD vs KLRS Comparison
BZFD vs KLRS Comparison
Compare BZFD & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BZFD | KLRS |
|---|---|---|
| Founded | 2006 | 2019 |
| Country | United States | United States |
| Employees | 507 | N/A |
| Industry | Movies/Entertainment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 91.7M | 92.8M |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | BZFD | KLRS |
|---|---|---|
| Price | $1.09 | $3.24 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $19.00 |
| AVG Volume (30 Days) | ★ 314.8K | 53.1K |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 75.70 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $185,266,000.00 | $165,000.00 |
| Revenue This Year | $1.69 | N/A |
| Revenue Next Year | $108.06 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.54 | $3.03 |
| 52 Week High | $2.21 | $11.88 |
Technical Indicators
Market Signals| Indicator | BZFD | KLRS |
|---|---|---|
| Relative Strength Index (RSI) | 49.69 | 32.33 |
| Support Level | $1.06 | $3.03 |
| Resistance Level | $1.27 | $4.37 |
| Average True Range (ATR) | 0.04 | 0.19 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 66.67 | 16.89 |
Price Performance
Historical ComparisonAbout BZFD BuzzFeed Inc.
BuzzFeed Inc is a digital media company across pop culture, entertainment, shopping, food, and news, its brands drive conversation and inspire what audiences watch, read, and buy now and into the future. Its iconic, globally-loved brands include BuzzFeed, HuffPost, and Tasty. The company generates revenue from advertising, content, commerce, and other sources.
About KLRS Kalaris Therapeutics Inc.
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.